首页 > 最新文献

Nephrology and Dialysis最新文献

英文 中文
Deficiency of glucose-6-phosphate dehydrogenase activity in the development of contrast-induced acute kidney injury 葡萄糖-6-磷酸脱氢酶活性缺乏在造影剂诱导的急性肾损伤发展中的作用
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-2-339-348
S.N. Zheregelya, S. Glushkov, A. I. Karpishchenko
{"title":"Deficiency of glucose-6-phosphate dehydrogenase activity in the development of contrast-induced acute kidney injury","authors":"S.N. Zheregelya, S. Glushkov, A. I. Karpishchenko","doi":"10.28996/2618-9801-2022-2-339-348","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-2-339-348","url":null,"abstract":"","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69400740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with quality of life in predialysis chronic kidney disease. Review of literature 透析前慢性肾病患者生活质量的相关因素文献综述
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-3-457-472
I. Vasilieva
Health-related quality of life (QoL) is one of the main patient-reported outcomes. Monitoring QoL in patients with chronic kidney disease (CKD) can be considered one of the approaches to the implementation of the principles of personalized medicine in clinical nephrology. The review provides a brief description of the questionnaires most used to assess QoL in patients with CKD and summarizes the results of studies of factors related to QoL at predialysis stages. It is customary to distinguish sociodemographic, clinical, and psychological factors associated with health-related QoL. Being female, smoking, low levels of education and income, the presence of coronary heart or cerebrovascular diseases, depression, and anxiety were shown to be associated with a decrease in QoL of patients with predialysis CKD. As for other clinical and socio-demographic factors, the literature data are not so unambiguous. Thus, several studies have demonstrated that a decrease in glomerular filtration rate, albumin and hemoglobin levels, the presence of diabetes, and an increase in age and creatinine level negatively affect the parameters of the physical component of QoL. At the same time, a significant number of studies have not found a relationship between these variables and the parameters of the psychosocial component of QoL, which is explained by the dependence of this QoL component primarily on the characteristics of the emotional state and personality. Of the psychological factors associated with QoL in patients with CKD treated conservatively, the attention of researchers was focused mainly on the level of depression. Only a few studies have analyzed other psychological variables (personality traits, coping strategies, effects of psychosocial interventions) related to QoL in patients with predialysis CKD. Identification and systematization of potentially modifiable factors affecting patients’ QoL set the directions for the prevention and correction of reduced QoL
健康相关生活质量(QoL)是患者报告的主要结局之一。监测慢性肾脏疾病(CKD)患者的生活质量可以被认为是在临床肾脏学中实施个性化医疗原则的方法之一。本文简要介绍了CKD患者最常用的生活质量评估问卷,并总结了透析前阶段生活质量相关因素的研究结果。习惯上区分与健康相关生活质量相关的社会人口、临床和心理因素。女性、吸烟、低教育水平和低收入、存在冠心病或脑血管疾病、抑郁和焦虑与透析前CKD患者的生活质量下降有关。至于其他临床和社会人口因素,文献数据并非如此明确。因此,一些研究表明,肾小球滤过率、白蛋白和血红蛋白水平的下降、糖尿病的存在以及年龄和肌酐水平的增加对生活质量的物理成分参数产生负面影响。同时,大量的研究没有发现这些变量与生活质量的社会心理成分参数之间的关系,这可以解释为生活质量成分主要依赖于情绪状态和人格特征。在CKD保守治疗患者生活质量的相关心理因素中,研究者的关注主要集中在抑郁水平上。只有少数研究分析了与透析前CKD患者生活质量相关的其他心理变量(人格特征、应对策略、心理社会干预的效果)。识别和系统化影响患者生活质量的潜在可改变因素,为预防和纠正生活质量下降指明了方向
{"title":"Factors associated with quality of life in predialysis chronic kidney disease. Review of literature","authors":"I. Vasilieva","doi":"10.28996/2618-9801-2022-3-457-472","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-3-457-472","url":null,"abstract":"Health-related quality of life (QoL) is one of the main patient-reported outcomes. Monitoring QoL in patients with chronic kidney disease (CKD) can be considered one of the approaches to the implementation of the principles of personalized medicine in clinical nephrology. The review provides a brief description of the questionnaires most used to assess QoL in patients with CKD and summarizes the results of studies of factors related to QoL at predialysis stages. It is customary to distinguish sociodemographic, clinical, and psychological factors associated with health-related QoL. Being female, smoking, low levels of education and income, the presence of coronary heart or cerebrovascular diseases, depression, and anxiety were shown to be associated with a decrease in QoL of patients with predialysis CKD. As for other clinical and socio-demographic factors, the literature data are not so unambiguous. Thus, several studies have demonstrated that a decrease in glomerular filtration rate, albumin and hemoglobin levels, the presence of diabetes, and an increase in age and creatinine level negatively affect the parameters of the physical component of QoL. At the same time, a significant number of studies have not found a relationship between these variables and the parameters of the psychosocial component of QoL, which is explained by the dependence of this QoL component primarily on the characteristics of the emotional state and personality. Of the psychological factors associated with QoL in patients with CKD treated conservatively, the attention of researchers was focused mainly on the level of depression. Only a few studies have analyzed other psychological variables (personality traits, coping strategies, effects of psychosocial interventions) related to QoL in patients with predialysis CKD. Identification and systematization of potentially modifiable factors affecting patients’ QoL set the directions for the prevention and correction of reduced QoL","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69401332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intranasal vasopressin (DDAVP) and intra-dialysis hypotension incidence in end-stage renal disease 终末期肾病患者鼻内抗利尿激素(DDAVP)和透析内低血压的发生率
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-3-480-485
A. Alidadi, Tahereh Mohammadi Fatideh
{"title":"Intranasal vasopressin (DDAVP) and intra-dialysis hypotension incidence in end-stage renal disease","authors":"A. Alidadi, Tahereh Mohammadi Fatideh","doi":"10.28996/2618-9801-2022-3-480-485","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-3-480-485","url":null,"abstract":"","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69401381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal dysfunction and current biomarkers of renal damage in HELLP syndrome and obstetric atypical hemolytic uremic syndrome HELLP综合征和产科非典型溶血性尿毒症综合征的肾功能障碍和当前肾损害的生物标志物
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-4-875-883
T. Kirsanova, N. Kozlovskaya, A. Balakireva, T. Fedorova
{"title":"Renal dysfunction and current biomarkers of renal damage in HELLP syndrome and obstetric atypical hemolytic uremic syndrome","authors":"T. Kirsanova, N. Kozlovskaya, A. Balakireva, T. Fedorova","doi":"10.28996/2618-9801-2022-4-875-883","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-4-875-883","url":null,"abstract":"","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69402273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Features of COVID-19 vaccine prophylaxis in renal graft recipients 肾移植受者COVID-19疫苗预防的特点
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-4-884-891
I.G. Kim, L. Novikova, N. Frolova, E. Volodina, C.C. Bochkareva, V. Vinogradov, I. Ostrovskaya, E. Ivanova, V. Berdinsky, M.E. Maltseva, I. Skryabina, A. Stolbova
{"title":"Features of COVID-19 vaccine prophylaxis in renal graft recipients","authors":"I.G. Kim, L. Novikova, N. Frolova, E. Volodina, C.C. Bochkareva, V. Vinogradov, I. Ostrovskaya, E. Ivanova, V. Berdinsky, M.E. Maltseva, I. Skryabina, A. Stolbova","doi":"10.28996/2618-9801-2022-4-884-891","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-4-884-891","url":null,"abstract":"","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69402416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The use of therapeutic plasma exchange in the severe forms of COVID-19 in patients with renal fаilure 重症COVID-19肾衰患者治疗性血浆置换的应用
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-2-279-291
N. Frolova, N. Tomilina, K. E. Loss, E. Stolyarevich, R. Iskhakov, G. Arbolishvili, M. Frolov, S. S. Usatiuk, Yu.V. Streltsov, L. Artyukhina, M. Zubkin, O. Kotenko, G. Volgina, M. Lysenko
Cytokine release syndrome plays a key role in the pathogenesis of COVID-19. Therapeutic plasma exchange (TPE) by removing pathogenic cytokines, can favorably influence the course of severe forms of this disease. However, conclusive studies on this issue are still lacking. Only descriptions of individual clinical cases or small cohort studies have been published. There are no data on the use of TPE in patients with renal failure in the literature. The study aims to evaluate the effect of TPE in the severe forms of COVID-19 in patients with advanced renal failure. Material and Methods: a retrospective, uncontrolled, observational study enrolled 211 patients aged 60,4±13,2. 90.5% of them received renal replacement therapy: 66.8% – hemodialysis, 9.5% – peritoneal dialysis, 14.2% renal transplant recipients with moderate to severe dysfunction, and 9.5% had acute kidney injury on chronic kidney disease that did not require dialysis treatment. Results. All patients were divided into 2 groups: 124 (58.8%) patients (treated from 01.07. to 15.12.2020), who received TPE (TPE group), and 87 (41.2%) patients (observed from 01.04. to 30.06.2020), who did not treat with TPE (control group). The condition of patients in both groups at admission was approximately comparable. The clinical picture of the disease was dominated by severe pneumonia. There were no significant differences in inflammatory markers: both groups had no significant differences in levels of CRP, ferritin, lactate dehydrogenase, or D-dimer. The groups also did not differ significantly in lymphopenia, thrombocytopenia, and azotemia. The mortality rate in the group of patients who did not receive TPE was 73.5%, while in the TPE group it was 45.16% (p<0.001). Among patients on chronic dialysis, the mortality rate in the control subgroup was 74.6%, and in the TPE subgroup – 44.15% (p<0.001). Conclusion:therapeutic plasma exchange is an efficient approach to the treatment of severe forms of COVID-19 in patients with advanced renal failure. Its effect, however, may be limited by the risk of death due to uremia. © 2022 JSC Vidal Rus. All rights reserved.
细胞因子释放综合征在COVID-19的发病机制中起关键作用。治疗性血浆交换(TPE)通过去除致病性细胞因子,可以积极影响严重形式的这种疾病的进程。然而,关于这一问题的结论性研究仍然缺乏。只发表了个别临床病例或小队列研究的描述。文献中没有关于肾衰患者使用TPE的数据。本研究旨在评估TPE在重症COVID-19合并晚期肾功能衰竭患者中的作用。材料和方法:一项回顾性、非对照、观察性研究,纳入211例患者,年龄60(4±13,2)岁。90.5%的人接受了肾脏替代治疗:66.8%的人接受血液透析,9.5%的人接受腹膜透析,14.2%的肾移植受者有中度至重度功能障碍,9.5%的人因慢性肾脏疾病而急性肾损伤,不需要透析治疗。结果。所有患者分为2组:124例(58.8%)例(从01.07开始治疗)。至2020年12月15日),接受TPE (TPE组)的患者87例(41.2%)。至30.06.2020),未进行TPE治疗(对照组)。两组患者入院时的情况大致相当。临床表现以重症肺炎为主。炎症标志物无显著差异:两组CRP、铁蛋白、乳酸脱氢酶或d -二聚体水平无显著差异。两组在淋巴细胞减少症、血小板减少症和氮血症方面也没有显著差异。未行TPE组的死亡率为73.5%,而TPE组的死亡率为45.16% (p<0.001)。在慢性透析患者中,对照组死亡率为74.6%,TPE亚组死亡率为44.15% (p<0.001)。结论:治疗性血浆置换是治疗重症COVID-19合并晚期肾功能衰竭患者的有效方法。然而,它的效果可能受到尿毒症死亡风险的限制。©2022 JSC Vidal Rus。版权所有。
{"title":"The use of therapeutic plasma exchange in the severe forms of COVID-19 in patients with renal fаilure","authors":"N. Frolova, N. Tomilina, K. E. Loss, E. Stolyarevich, R. Iskhakov, G. Arbolishvili, M. Frolov, S. S. Usatiuk, Yu.V. Streltsov, L. Artyukhina, M. Zubkin, O. Kotenko, G. Volgina, M. Lysenko","doi":"10.28996/2618-9801-2022-2-279-291","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-2-279-291","url":null,"abstract":"Cytokine release syndrome plays a key role in the pathogenesis of COVID-19. Therapeutic plasma exchange (TPE) by removing pathogenic cytokines, can favorably influence the course of severe forms of this disease. However, conclusive studies on this issue are still lacking. Only descriptions of individual clinical cases or small cohort studies have been published. There are no data on the use of TPE in patients with renal failure in the literature. The study aims to evaluate the effect of TPE in the severe forms of COVID-19 in patients with advanced renal failure. Material and Methods: a retrospective, uncontrolled, observational study enrolled 211 patients aged 60,4±13,2. 90.5% of them received renal replacement therapy: 66.8% – hemodialysis, 9.5% – peritoneal dialysis, 14.2% renal transplant recipients with moderate to severe dysfunction, and 9.5% had acute kidney injury on chronic kidney disease that did not require dialysis treatment. Results. All patients were divided into 2 groups: 124 (58.8%) patients (treated from 01.07. to 15.12.2020), who received TPE (TPE group), and 87 (41.2%) patients (observed from 01.04. to 30.06.2020), who did not treat with TPE (control group). The condition of patients in both groups at admission was approximately comparable. The clinical picture of the disease was dominated by severe pneumonia. There were no significant differences in inflammatory markers: both groups had no significant differences in levels of CRP, ferritin, lactate dehydrogenase, or D-dimer. The groups also did not differ significantly in lymphopenia, thrombocytopenia, and azotemia. The mortality rate in the group of patients who did not receive TPE was 73.5%, while in the TPE group it was 45.16% (p<0.001). Among patients on chronic dialysis, the mortality rate in the control subgroup was 74.6%, and in the TPE subgroup – 44.15% (p<0.001). Conclusion:therapeutic plasma exchange is an efficient approach to the treatment of severe forms of COVID-19 in patients with advanced renal failure. Its effect, however, may be limited by the risk of death due to uremia. © 2022 JSC Vidal Rus. All rights reserved.","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69399409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ATTR-amyloidosis - a systemic disease involving the kidneys atr -淀粉样变-一种累及肾脏的全身性疾病
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-3-441-456
L. I. Anikonova, O. Vorobyeva, N. Bakulina
ATTR amyloidosis (transthyretin amyloidosis) is a progressive, fatal disease characterized by the accumulation of transthyretin amyloid mainly in the peripheral nervous system (somatic and autonomic) and heart, as well as in the kidneys, gastrointestinal tract, eyeballs, and ligaments, which impairs the normal function of organs and systems. The hereditary form of ATTR amyloidosis, or ATTRv amyloidosis, is found all over the world and is characterized by broad genetic and phenotypic heterogeneity, resulting in late diagnosis. The kidneys are a potential target organ in ATTRv amyloidosis. Clinically, nephropathy is manifested by albuminuria, proteinuria, nephrotic syndrome, or decreased renal function. A nephrologist may be involved in the diagnosis of amyloid nephropathy/ATTRv amyloidosis in a patient with symptoms of renal damage in an endemic region or with a family history of ATTRv amyloidosis, or, more difficult, in the diagnosis of a sporadic case of ATTRv amyloidosis when symptoms of nephropathy were detected in a patient in a non-endemic region without a known family history of amyloidosis. The diagnosis of amyloidosis, especially is sporadic cases, requires the nephrologist to know the specific symptoms, the so-called "red flags" of ATTR amyloidosis that allow suspecting amyloidosis, and methods to confirm the diagnosis. Kidney biopsy in the presence of nephropathy is the gold standard in the diagnosis of amyloidosis. Congo-red staining of biopsy specimens with subsequent visualization of the apple-green birefringence of congophilic masses with polarized light is crucial for histological confirmation of the diagnosis. Immunohistochemistry is used for amyloid typing. The less available method for typing is mass spectrometry of affected tissue. Detection of "red flags" of amyloidosis in a patient with nephropathy makes it possible to diagnose ATTR amyloidosis in some cases without a biopsy, by TTR gene sequencing or myocardial scintigraphy with 99mTc-pyrophosphate. After amyloidosis is diagnosed, it is necessary to conduct a detailed examination for assessing the damage to potential target organs, which requires an interdisciplinary approach. Early diagnosis and disease-modifying therapies can slow the progression of neuropathy and cardiomyopathy, and presumably nephropathy.
ATTR淀粉样变性(转甲状腺素淀粉样变性)是一种进行性、致死性疾病,其特征是转甲状腺素淀粉样蛋白主要在周围神经系统(躯体和自主神经)和心脏以及肾脏、胃肠道、眼球和韧带中积累,损害器官和系统的正常功能。ATTR淀粉样变或attv淀粉样变的遗传形式在世界各地都有发现,其特征是广泛的遗传和表型异质性,导致诊断较晚。肾脏是ATTRv淀粉样变的潜在靶器官。临床上,肾病表现为蛋白尿、蛋白尿、肾病综合征或肾功能下降。肾病科医生可能会参与到淀粉样肾病/ATTRv淀粉样变性的诊断中,如果患者在流行地区有肾损害症状或有ATTRv淀粉样变性家族史,或者更困难的是,当在非流行地区的患者中发现肾病症状而没有已知的淀粉样变性家族史时,肾病科医生可能会参与到散发的ATTRv淀粉样变性的诊断中。淀粉样变的诊断,特别是零星病例的诊断,需要肾脏科医生了解具体的症状,所谓的ATTR淀粉样变的“危险信号”,允许怀疑淀粉样变,以及确认诊断的方法。肾病患者行肾活检是淀粉样变诊断的金标准。对活检标本进行刚果红染色,并在偏光下显示苹果绿色双折射的嗜血性肿块,这对组织学诊断的确认至关重要。免疫组织化学用于淀粉样蛋白分型。较不可行的分型方法是受影响组织的质谱分析。在肾病患者中检测到淀粉样变的“红旗”,使得在某些情况下无需活检,通过TTR基因测序或99mtc焦磷酸盐心肌闪烁成像即可诊断ATTR淀粉样变。淀粉样变诊断后,需要进行详细的检查,以评估潜在靶器官的损害,这需要跨学科的方法。早期诊断和疾病改善治疗可以减缓神经病变和心肌病的进展,可能还有肾病。
{"title":"ATTR-amyloidosis - a systemic disease involving the kidneys","authors":"L. I. Anikonova, O. Vorobyeva, N. Bakulina","doi":"10.28996/2618-9801-2022-3-441-456","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-3-441-456","url":null,"abstract":"ATTR amyloidosis (transthyretin amyloidosis) is a progressive, fatal disease characterized by the accumulation of transthyretin amyloid mainly in the peripheral nervous system (somatic and autonomic) and heart, as well as in the kidneys, gastrointestinal tract, eyeballs, and ligaments, which impairs the normal function of organs and systems. The hereditary form of ATTR amyloidosis, or ATTRv amyloidosis, is found all over the world and is characterized by broad genetic and phenotypic heterogeneity, resulting in late diagnosis. The kidneys are a potential target organ in ATTRv amyloidosis. Clinically, nephropathy is manifested by albuminuria, proteinuria, nephrotic syndrome, or decreased renal function. A nephrologist may be involved in the diagnosis of amyloid nephropathy/ATTRv amyloidosis in a patient with symptoms of renal damage in an endemic region or with a family history of ATTRv amyloidosis, or, more difficult, in the diagnosis of a sporadic case of ATTRv amyloidosis when symptoms of nephropathy were detected in a patient in a non-endemic region without a known family history of amyloidosis. The diagnosis of amyloidosis, especially is sporadic cases, requires the nephrologist to know the specific symptoms, the so-called \"red flags\" of ATTR amyloidosis that allow suspecting amyloidosis, and methods to confirm the diagnosis. Kidney biopsy in the presence of nephropathy is the gold standard in the diagnosis of amyloidosis. Congo-red staining of biopsy specimens with subsequent visualization of the apple-green birefringence of congophilic masses with polarized light is crucial for histological confirmation of the diagnosis. Immunohistochemistry is used for amyloid typing. The less available method for typing is mass spectrometry of affected tissue. Detection of \"red flags\" of amyloidosis in a patient with nephropathy makes it possible to diagnose ATTR amyloidosis in some cases without a biopsy, by TTR gene sequencing or myocardial scintigraphy with 99mTc-pyrophosphate. After amyloidosis is diagnosed, it is necessary to conduct a detailed examination for assessing the damage to potential target organs, which requires an interdisciplinary approach. Early diagnosis and disease-modifying therapies can slow the progression of neuropathy and cardiomyopathy, and presumably nephropathy.","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69401325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profiling of sodium and ultrafiltration at patients on a program hemodialysis: Focus on quality of life 血液透析患者的钠和超滤分析:关注生活质量
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-3-473-479
A. Litun, Z. Simonova, E. Kolmakova
{"title":"Profiling of sodium and ultrafiltration at patients on a program hemodialysis: Focus on quality of life","authors":"A. Litun, Z. Simonova, E. Kolmakova","doi":"10.28996/2618-9801-2022-3-473-479","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-3-473-479","url":null,"abstract":"","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69401373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors identification of respiratory tuberculosis progression in patients with end-stage renal disease 终末期肾病患者呼吸结核进展的危险因素鉴定
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-3-494-501
O. Gordeeva, N. Karpina
{"title":"Risk factors identification of respiratory tuberculosis progression in patients with end-stage renal disease","authors":"O. Gordeeva, N. Karpina","doi":"10.28996/2618-9801-2022-3-494-501","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-3-494-501","url":null,"abstract":"","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69401526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trauma of the central vessels, which led to profuse bleeding, after tunneled dialysis catheter insertion in patients treated with hemodialysis 血液透析患者隧道透析置管后中央血管损伤导致大量出血
Pub Date : 2022-01-01 DOI: 10.28996/2618-9801-2022-3-519-528
A. Yankovoy, A. Zulkarnaev
The need for central venous catheters in patients on hemodialysis is very high. Even though complications of catheter implantation are rare (on average about 0.5% of cases, according to own data - 0.37%), their treatment is extremely difficult and, in most cases, requires a large surgery. We present four clinical observations. In the first case, during the puncture was damaged the left subclavian vein in the area of its fixation to the first rib and confluence with the internal jugular vein. The resulting heavy bleeding required a thoracotomy, the bleeding was stopped. The patient was discharged. In the second case, there was damage to the left common carotid artery. The defect was eliminated during the operation. The patient was discharged. In the third case, the right common carotid artery was damaged. During the first hours after the injury, the local hematoma did not grow, the condition remained stable. Four hours after physical exertion (stool), there was a rapid increase in hematoma, compression of the trachea, and suffocation. Attempts to intubate were unsuccessful. An emergency tracheostomy was performed. Despite this, the patient died. In the fourth case, the upper vena cava was damaged. In this case, the catheter was located in the projection of the right atrium on the frontal x-ray. The pleural cavity was drained. In connection with the ongoing bleeding on the pleural drainage, an emergency computer tomography was performed, where it was found that the catheter perforates the vein and was located in the pleural cavity. An emergency thoracotomy was performed, the vein defect was eliminated. The patient was discharged after long-term treatment. Thus, a series of clinical observations demonstrate that the diagnosis of severe complications of large vessel damage during the dialysis catheters implantation is difficult due to several factors: the patient's condition, anatomical features, comorbid background, and many localizations of possible damage to vessels. Complicated catheter implantation requires mandatory ultrasound control, observation in the intensive care unit, mandatory x-ray examination, and, if necessary, computer tomography for early detection of life-threatening conditions.
血液透析患者对中心静脉导管的需求非常高。尽管导管植入的并发症很少见(平均约0.5%的病例,根据自己的数据- 0.37%),但它们的治疗非常困难,在大多数情况下,需要进行大手术。我们提出了四个临床观察。在第一例中,在穿刺过程中,左锁骨下静脉与第一肋骨固定并与颈内静脉汇合的区域被破坏。导致大量出血,需要开胸手术,出血被止住。病人出院了。在第二个病例中,左侧颈总动脉受损。这个缺陷在手术中被消除了。病人出院了。在第三例中,右颈总动脉受损。在受伤后的最初几个小时内,局部血肿没有增长,病情保持稳定。体力消耗(大便)4小时后,血肿迅速增加,气管受压,窒息。尝试插管失败。进行了紧急气管切开术。尽管如此,病人还是死了。在第四个病例中,上腔静脉受损。在本例中,导管位于正位x线上的右心房投影处。胸腔引流。由于胸膜引流管持续出血,对其进行了紧急计算机断层扫描,发现导管穿过静脉并位于胸膜腔内。急诊开胸,静脉缺损消除。患者经长期治疗出院。因此,一系列的临床观察表明,由于患者的病情、解剖特征、合并症背景以及许多可能的血管损伤定位等因素,诊断透析导管植入过程中大血管损伤的严重并发症是困难的。复杂的导管植入需要强制超声控制,在重症监护病房观察,强制x线检查,必要时进行计算机断层扫描,以早期发现危及生命的疾病。
{"title":"Trauma of the central vessels, which led to profuse bleeding, after tunneled dialysis catheter insertion in patients treated with hemodialysis","authors":"A. Yankovoy, A. Zulkarnaev","doi":"10.28996/2618-9801-2022-3-519-528","DOIUrl":"https://doi.org/10.28996/2618-9801-2022-3-519-528","url":null,"abstract":"The need for central venous catheters in patients on hemodialysis is very high. Even though complications of catheter implantation are rare (on average about 0.5% of cases, according to own data - 0.37%), their treatment is extremely difficult and, in most cases, requires a large surgery. We present four clinical observations. In the first case, during the puncture was damaged the left subclavian vein in the area of its fixation to the first rib and confluence with the internal jugular vein. The resulting heavy bleeding required a thoracotomy, the bleeding was stopped. The patient was discharged. In the second case, there was damage to the left common carotid artery. The defect was eliminated during the operation. The patient was discharged. In the third case, the right common carotid artery was damaged. During the first hours after the injury, the local hematoma did not grow, the condition remained stable. Four hours after physical exertion (stool), there was a rapid increase in hematoma, compression of the trachea, and suffocation. Attempts to intubate were unsuccessful. An emergency tracheostomy was performed. Despite this, the patient died. In the fourth case, the upper vena cava was damaged. In this case, the catheter was located in the projection of the right atrium on the frontal x-ray. The pleural cavity was drained. In connection with the ongoing bleeding on the pleural drainage, an emergency computer tomography was performed, where it was found that the catheter perforates the vein and was located in the pleural cavity. An emergency thoracotomy was performed, the vein defect was eliminated. The patient was discharged after long-term treatment. Thus, a series of clinical observations demonstrate that the diagnosis of severe complications of large vessel damage during the dialysis catheters implantation is difficult due to several factors: the patient's condition, anatomical features, comorbid background, and many localizations of possible damage to vessels. Complicated catheter implantation requires mandatory ultrasound control, observation in the intensive care unit, mandatory x-ray examination, and, if necessary, computer tomography for early detection of life-threatening conditions.","PeriodicalId":52208,"journal":{"name":"Nephrology and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69401944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nephrology and Dialysis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1